Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Ectoparasitic Infestations; Lice Infestations; Otitis Externa; Pruritus
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Hepatocellular; Colorectal Neoplasms; Corneal Neovascularization; Glioblastoma; Lymphoma; Psoriasis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chondrosarcoma; Dermatofibrosarcoma; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Gliosarcoma; Hemangiosarcoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Lung Neoplasms; Lymphedema; Macular Degeneration; Melanoma; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumors; Osteosarcoma; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Salivary Gland Neoplasms; Sarcoma, Alveolar Soft Part; Small Cell Lung Carcinoma; Solitary Fibrous Tumors; Stomach Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Sarcoma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ferriprotoporphyrin IX inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: HIV Infections; Neoplasms; Schistosomiasis haematobia; Fever; Malaria, Falciparum; Malaria, Vivax; Malaria
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: FK506-binding protein 1A inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; IMMUNE SYSTEM; OTHER; UROLOGY AND KIDNEY
THERAPEUTIC INDICATION: Acute Coronary Syndrome; Adenocarcinoma; Breast Neoplasms, Male; Carcinoma, Ovarian Epithelial; Central Nervous System Neoplasms; Colonic Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Hamartoma Syndrome, Multiple; Hematologic Diseases; Leukemia; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Peritoneal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Progeria; Sarcoma, Synovial; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Adenoma, Islet Cell; Brain Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Chondrosarcoma; Colorectal Neoplasms; Endometrial Hyperplasia; Endometrial Neoplasms; Ependymoma; Epilepsy; Glioblastoma; Glioma; Head and Neck Neoplasms; Hepatitis C; Hodgkin Disease; Hyperaldosteronism; Kidney Diseases; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphangioleiomyomatosis; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, T-Cell, Cutaneous; Macular Degeneration; Mastocytosis, Systemic; Melanoma; Meningioma; Mesothelioma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Germ Cell and Embryonal; Neurilemmoma; Neurofibromatosis 1; Neurofibromatosis 2; Oligodendroglioma; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peutz-Jeghers Syndrome; Polycystic Kidney Diseases; Sarcoma; Sarcoma, Kaposi; Small Cell Lung Carcinoma; Thymus Neoplasms; Thyroid Neoplasms; Tuberculosis; Urinary Bladder Neoplasms; Uterine Neoplasms; Uveitis; Waldenstrom Macroglobulinemia; Carcinoid Tumor; Carcinoma; Coronary Restenosis; Cytomegalovirus Infections; Diffuse Intrinsic Pontine Glioma; Endocardial Cushion Defects; Graft vs Host Disease; Infections; Kidney Neoplasms; Lymphoma, Large B-Cell, Diffuse; Malignant Carcinoid Syndrome; Polycystic Kidney, Autosomal Dominant; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Renal Insufficiency, Chronic; Skin Neoplasms; Stomach Neoplasms; Angiomyolipoma; Astrocytoma; Breast Neoplasms; Carcinoma, Renal Cell; Immune System Diseases; Neoplasms; Neuroendocrine Tumors; Tuberous Sclerosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dihydrofolate reductase inhibitor
ROUTE OF ADMINISTRATION: INJECTION; INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: CANCER; OTHER
THERAPEUTIC INDICATION: Fallopian Tube Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Multiple Myeloma; Mycosis Fungoides; Ovarian Neoplasms; Peritoneal Neoplasms; Sezary Syndrome; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Lung Neoplasms; Lymphoma; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ferriprotoporphyrin IX inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: HIV Infections; Schistosomiasis haematobia; Fever; Malaria, Falciparum; Malaria, Vivax; Malaria
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Irritable Bowel Syndrome; Low Back Pain; Neuralgia; Fibromyalgia; Peripheral Nervous System Diseases; Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Atrial Fibrillation; Atrial Flutter; Heart Failure; Arrhythmias, Cardiac
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Endothelin receptor, ET-A/ET-B antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: RESPIRATORY
THERAPEUTIC INDICATION: Glioblastoma; Heart Failure; Idiopathic Pulmonary Fibrosis; Hernias, Diaphragmatic, Congenital; Hypertension, Pulmonary; Scleroderma, Systemic; Ulcer; Familial Primary Pulmonary Hypertension; Hypertension
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Autistic Disorder; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Major; Schizophrenia; Psychotic Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tubulin inhibitor
ROUTE OF ADMINISTRATION: INJECTION; INTRAVENOUS; IV (INFUSION)
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Brain Neoplasms; Glioma; Adrenal Cortex Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Liposarcoma; Ovarian Neoplasms; Penile Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Neoplasms; Prostatic Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; DERMATOLOGY; OTHER
THERAPEUTIC INDICATION: Cheilitis; Warts; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Condylomata Acuminata; Keratosis; Keratosis, Seborrheic; Lentigo; Skin Diseases; Keratosis, Actinic
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Voltage-gated potassium channel blocker
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: MUSCULOSKELETAL
THERAPEUTIC INDICATION: Cerebral Palsy; Motor Neuron Disease; Renal Insufficiency; Guillain-Barre Syndrome; Muscular Atrophy, Spinal; Prostatic Diseases; Sleep Apnea, Obstructive; Trauma, Nervous System; Ischemic Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Muscle Spasticity; Spinal Cord Injuries; Stroke; Multiple Sclerosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hematologic Diseases; Non-alcoholic Fatty Liver Disease; Prostatic Neoplasms; Renal Insufficiency; Renal Insufficiency, Chronic; Coronary Disease; Atrial Fibrillation; Stroke; Thromboembolism; Venous Thromboembolism; Venous Thrombosis; Thrombosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: MUSCULOSKELETAL
THERAPEUTIC INDICATION: Breast Neoplasms; Renal Insufficiency; Rett Syndrome; Asthma; Optic Neuritis; Schizophrenia; Severe Acute Respiratory Syndrome; Stroke; Uveitis; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Immune System Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY; OTHER
THERAPEUTIC INDICATION: Hemorrhoids; Macular Degeneration; Melanoma; Tennis Elbow; Telangiectasis; Varicose Veins
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Anorexia Nervosa; Dysmenorrhea; Endometriosis; Metrorrhagia; Menorrhagia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Uterine Cervical Dysplasia; Cervical Intraepithelial Neoplasia; Lichen Planus
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Histamine H1 receptor antagonist
ROUTE OF ADMINISTRATION: OPHTHALMIC
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Conjunctivitis, Allergic; Eye Manifestations
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: OTHER; RESPIRATORY
THERAPEUTIC INDICATION: Kidney Diseases; Meningitis; Systemic Inflammatory Response Syndrome; Sepsis; Urinary Tract Infections; Infections; Influenza, Human; Pneumonia; Pneumonia, Bacterial; Severe Acute Respiratory Syndrome; Bacterial Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bcr/Abl fusion protein
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Amyotrophic Lateral Sclerosis; Blast Crisis; Carcinoma, Non-Small-Cell Lung; Dementia; Leukemia, Myeloid, Acute; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thymoma; Thymus Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Breast Neoplasms; Glioblastoma; Leukemia; Polycystic Kidney, Autosomal Dominant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Carbamoyl-phosphate synthase [ammonia], mitochondrial positive allosteric modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: UROLOGY AND KIDNEY
THERAPEUTIC INDICATION: Metabolism, Inborn Errors; Propionic Acidemia; Hyperammonemia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Renal Cell; Fallopian Tube Neoplasms; Melanoma; Ovarian Neoplasms; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Hereditary Breast and Ovarian Cancer Syndrome; Inflammatory Breast Neoplasms; Sarcoma; Solitary Fibrous Tumors; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Essential Hypertension; Hypertension; Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Pancreatic Ductal; Dermatitis; Glioblastoma; Leukemia, Biphenotypic, Acute; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pneumonia; Alopecia Areata; Arthritis, Rheumatoid; Breast Neoplasms; Bronchiolitis Obliterans; Cachexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; HIV Infections; Hematologic Neoplasms; Hidradenitis Suppurativa; Hodgkin Disease; Hypereosinophilic Syndrome; Inflammatory Breast Neoplasms; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lichen Planus; Lupus Erythematosus, Discoid; Lymphoma; Multiple Myeloma; Necrobiosis Lipoidica; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms, Castration-Resistant; Psoriasis; Thrombocythemia, Essential; beta-Thalassemia; Dermatitis, Atopic; Eczema; Graft vs Host Disease; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Myeloproliferative Disorders; Pancreatic Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Severe Acute Respiratory Syndrome; Vitiligo; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dipeptidyl peptidase IV inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: DIABETES DRUGS & ENDOCRINOLOGY
THERAPEUTIC INDICATION: Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Hypertension; Renal Insufficiency; Schizophrenia; Stomach Neoplasms; Respiratory Tract Diseases; Severe Acute Respiratory Syndrome; Diabetes Mellitus; Diabetes Mellitus, Type 2
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium/glucose cotransporter 2 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: DIABETES DRUGS & ENDOCRINOLOGY; OTHER
THERAPEUTIC INDICATION: Polycystic Ovary Syndrome; Renal Insufficiency; Breast Neoplasms; Diabetes Mellitus, Type 1; Obesity; Diabetic Nephropathies; Heart Failure; Diabetes Mellitus; Diabetes Mellitus, Type 2
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Beta-2 adrenergic receptor agonist
ROUTE OF ADMINISTRATION: INHALATION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Asthma; Bronchitis, Chronic; Emphysema; Pulmonary Disease, Chronic Obstructive
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Serine/threonine-protein kinase B-raf inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY
THERAPEUTIC INDICATION: Lymphoma; Skin Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Craniopharyngioma; Histiocytosis; Histiocytosis, Langerhans-Cell; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Multiple Myeloma; Pancreatic Neoplasms; Thyroid Neoplasms; Melanoma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ephrin receptor inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Central Nervous System Neoplasms; Diffuse Intrinsic Pontine Glioma; Esophageal Neoplasms; Glioblastoma; Glioma; Neuroblastoma; Rectal Neoplasms; Adenocarcinoma, Follicular; Astrocytoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Colorectal Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Gliosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Mesothelioma; Multiple Myeloma; Neoplasm Metastasis; Oligodendroglioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Small Cell Lung Carcinoma; Stomach Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Medullary; Neoplasms; Thyroid Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Hepatitis C virus serine protease, NS3/NS4A inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM
THERAPEUTIC INDICATION: Thrombocytopenia; Hepatitis C; Hepatitis C, Chronic; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Purinergic receptor P2Y12 negative allosteric modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CARDIOVASCULAR
THERAPEUTIC INDICATION: Cardiovascular Diseases; Ischemia; Kidney Diseases; Aortic Aneurysm, Abdominal; Carotid Stenosis; Pulmonary Disease, Chronic Obstructive; Anemia, Sickle Cell; Angina, Stable; Aortic Valve Stenosis; Atrial Fibrillation; Influenza, Human; Intracranial Aneurysm; Non-ST Elevated Myocardial Infarction; Peripheral Arterial Disease; Pneumonia; Renal Insufficiency, Chronic; ST Elevation Myocardial Infarction; Severe Acute Respiratory Syndrome; Acute Coronary Syndrome; Coronary Artery Disease; Diabetes Mellitus, Type 2; Myocardial Infarction; Stroke; Thrombosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: ALK tyrosine kinase receptor inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; OTHER; RESPIRATORY
THERAPEUTIC INDICATION: Breast Neoplasms; Colorectal Neoplasms; Diffuse Intrinsic Pontine Glioma; Glioblastoma; Kidney Diseases; Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Adenocarcinoma; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Endometrial Neoplasms; Granuloma, Plasma Cell; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Multiple Myeloma; Neurofibromatosis 2; Stomach Neoplasms; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large B-Cell, Diffuse; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Heart Arrest
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Voltage-gated calcium channel modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY; NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Kidney Diseases; Alcoholism; Diabetic Neuropathies; Migraine Disorders; Epilepsy; Neuralgia, Postherpetic; Restless Legs Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown